Stockscreener 앱 받기
37.84
1.45%
0.54
시간 외 거래:
37.84
전일 마감가:
$37.30
열려 있는:
$37.06
하루 거래량:
4.74M
Relative Volume:
1.23
시가총액:
$16.36B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
16.47
EPS:
2.297
순현금흐름:
$827.02M
1주 성능:
+3.93%
1개월 성능:
+4.91%
6개월 성능:
+15.05%
1년 성능:
+39.12%
1일 변동 폭
$36.76
$38.09
1주일 범위
$36.23
$38.09
52주 변동 폭
$24.05
$38.09
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.84 | 16.12B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Can Royalty Pharma plc stock rebound after recent weaknessJuly 2025 Trends & Stepwise Trade Signal Implementation - newser.com
Royalty Pharma stock hits 52-week high at 38.01 USD - Investing.com
Royalty Pharma acquires AMVUTTRA royalty interest for $310 million - Investing.com
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative
Royalty Pharma acquires AMVUTTRA royalty for $310 million - StreetInsider
Royalty Pharma (NASDAQ: RPRX) acquires 1% AMVUTTRA royalty for $310M from Blackstone - Stock Titan
Is Royalty Pharma plc reversing from oversold territory2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Using Python tools to backtest Royalty Pharma plc strategies2025 Volume Leaders & Fast Gain Swing Trade Alerts - newser.com
Quantitative breakdown of Royalty Pharma plc recent moveTrade Signal Summary & Real-Time Stock Price Movement Reports - newser.com
Corton Capital Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Applying chart zones and confluence areas to Royalty Pharma plcMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com
Royalty Pharma PLC $RPRX Shares Purchased by Strs Ohio - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correctionExit Point & Consistent Return Investment Signals - newser.com
How Royalty Pharma plc (RPD) stock performs in easing cyclesForecast Cut & Long-Term Growth Plans - newser.com
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings - Yahoo! Finance UK
Royalty Pharma PLC $RPRX is Torray Investment Partners LLC's 3rd Largest Position - MarketBeat
Tredje AP fonden Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc (RPD) stock maintain strong growthPortfolio Return Report & Community Trade Idea Sharing - newser.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsJobs Report & Weekly Breakout Opportunity Watchlist - newser.com
Is Royalty Pharma plc stock a top momentum playWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
What the charts say about Royalty Pharma plc today2025 Price Momentum & Scalable Portfolio Growth Methods - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next year2025 Technical Overview & Safe Entry Trade Signal Reports - newser.com
Why Royalty Pharma plc (RPD) stock could rally stronglyStock Surge & Long-Term Safe Investment Plans - newser.com
What MACD signals say about Royalty Pharma plcMarket Movement Recap & Low Risk Investment Opportunities - newser.com
8,849 Shares in Royalty Pharma PLC $RPRX Acquired by MMA Asset Management LLC - MarketBeat
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 9th Largest Position - MarketBeat
Top chart patterns to watch in Royalty Pharma plcStock Surge & Risk Managed Investment Strategies - newser.com
Is Royalty Pharma plc stock a safe investment in uncertain marketsWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
Royalty Pharma plc : Close to an important technical resistance levels - MarketScreener
Why analysts remain bullish on Royalty Pharma plc stockEarnings Trend Report & AI Enhanced Trading Alerts - newser.com
Historical volatility pattern of Royalty Pharma plc visualizedLong Setup & Risk Controlled Swing Alerts - newser.com
Can Royalty Pharma plc stock beat analyst upgradesProfit Target & Fast Gain Swing Trade Alerts - newser.com
Detecting support and resistance levels for Royalty Pharma plcMarket Trend Report & Fast Entry Momentum Alerts - newser.com
28,646 Shares in Royalty Pharma PLC $RPRX Bought by Nisa Investment Advisors LLC - MarketBeat
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks - MSN
Royalty Pharma (NASDAQ:RPRX) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
What drives Royalty Pharma plc stock priceMarket Sentiment Extremes & Low Risk Trading Ideas - earlytimes.in
Royalty Pharma PLC $RPRX Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
0.86%
자본화:
|
볼륨(24시간):